Viewing Study NCT04906993


Ignite Creation Date: 2025-12-25 @ 1:04 AM
Ignite Modification Date: 2026-01-01 @ 11:49 PM
Study NCT ID: NCT04906993
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-09
First Post: 2021-05-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module